LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Inicio・Lista de Acciones・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Cerrado

SectorSanidad

2.69 -0.74

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.66

Máximo

2.7199999999999998

Métricas clave
By Trading Economics
Ingresos	4.1M -5.7M
Empleados	34
EBITDA	3.1M -6.8M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+640.74% upside

Dividendos
By Dow Jones
Próximas Ganancias	26 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-122M 267M
Apertura anterior	3.43
Cierre anterior	2.69

Noticias sobre sentimiento de mercado

By Acuity

91%

324 / 345 Clasificación en Healthcare

Anavex Life Sciences Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

22 may 2026, 16:33 UTC

Ganancias

Principales Movimientos del Mercado

Webull Shares Slide on 1Q Loss, Soaring Costs

22 may 2026, 21:10 UTC

Ganancias

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 may 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

22 may 2026, 20:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

22 may 2026, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

22 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

22 may 2026, 19:47 UTC

Ganancias

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 may 2026, 19:17 UTC

Charlas de Mercado

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 may 2026, 19:10 UTC

Charlas de Mercado

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 may 2026, 18:54 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

22 may 2026, 18:54 UTC

Charlas de Mercado

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 may 2026, 18:38 UTC

Charlas de Mercado

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 may 2026, 18:35 UTC

Adquisiciones, fusiones, absorciones

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 may 2026, 18:09 UTC

Charlas de Mercado

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 may 2026, 17:58 UTC

Charlas de Mercado

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

22 may 2026, 17:54 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

22 may 2026, 17:54 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 may 2026, 17:54 UTC

Charlas de Mercado

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

22 may 2026, 17:03 UTC

Charlas de Mercado

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

22 may 2026, 16:54 UTC

Charlas de Mercado

Crypto Spot Volumes Fall 14% in April -- Market Talk

22 may 2026, 16:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

22 may 2026, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

22 may 2026, 16:20 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

22 may 2026, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

22 may 2026, 16:16 UTC

Charlas de Mercado

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

22 may 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

22 may 2026, 15:55 UTC

Charlas de Mercado

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

22 may 2026, 15:42 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 may 2026, 15:42 UTC

Charlas de Mercado

Oil Continues as Leading Indicator for All Markets -- Market Talk

22 may 2026, 15:35 UTC

Charlas de Mercado

Gas Prices May Limit Spread of Inflationary Pressures in Canada -- Market Talk

Comparación entre iguales

Cambio de precio

Anavex Life Sciences Corp previsión

Precio Objetivo

By TipRanks

640.74% repunte

Estimación a 12 Meses

Media 20 USD 640.74%

Máximo 20 USD

Mínimo 20 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Sentimiento

By Acuity

324 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.